---
title: "TET2"
date: 2023-05-16 00:00:00
layout: post
categories: Gene
summary: "## Gene Information"
tags: ['TET2', 'DNA', 'demethylation', 'hematologicalmalignancies', 'prognosis', 'chemotherapy', 'drugresponse', 'mutation']
---

## Gene Information

TET2 is a protein-coding gene located on chromosome 4q24. It spans approximately 200 kilobases and encodes for a protein that is a member of the TET family of dioxygenases. TET2 is primarily involved in DNA demethylation, which regulates gene expression, and abnormalities in TET2 have been linked to tumorigenesis and hematological malignancies.

## Function

TET2 encodes a methylcytosine dioxygenase which catalyzes the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC). This process plays an important role in DNA demethylation, which is a critical process for regulating gene expression.

## External IDs and Aliases

- HGNC ID: 11616
- NCBI Entrez Gene ID: 54790
- Ensembl Gene ID: ENSG00000138155
- OMIM ID: 612839
- UniProtKB/Swiss-Prot ID: Q6N021
- Other aliases: CXXC8, TET-2, TET2B

## AA Mutation List and Mutation Type with dbSNP ID

- c.3344_3345delGT (p.Val1115Serfs*2) frameshift mutation with dbSNP ID rs398122674
- c.3736_3737insCC (p.Thr1246Profs*41) frameshift mutation with dbSNP ID rs3892103
- c.3454C>T (p.Pro1152Leu) missense mutation with dbSNP ID rs1558542456

## Somatic SNVs/InDels with dbSNP ID

- c.1121A>G (p.Tyr374Cys) missense mutation with dbSNP ID rs1566856
- c.3685C>T (p.Ser1229Leu) missense mutation with dbSNP ID rs766385427

## Related Disease

Mutations in TET2 have been identified in a variety of hematological malignancies, including myelodysplastic syndromes, acute myeloid leukemia, and myeloproliferative neoplasms.

## Treatment and Prognosis

The prognosis and treatment of TET2 mutations in hematological malignancies are complex and depend on many factors, including disease stage, age, and overall health. Treatment may involve chemotherapy, radiation therapy, bone marrow transplant, or targeted therapies.

## Drug Response

There is limited information regarding the drug response of TET2 mutations in hematological malignancies. However, some studies suggest that TET2 mutations may confer resistance to chemotherapy.

## Related Papers

- Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009 May 28;360(22):2289-301. doi: 10.1056/NEJMoa0810069. PMID: 19474426.
- Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012 Aug 30;367(9):878-81. doi: 10.1056/NEJMc1207123. PMID: 22931317.
- Quivoron C, Couronne L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011 Feb 15;20(2):25doi: 10.1016/j.ccr.2011.07.008. PMID: 21907924.

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**